Entasis Awards

Entasis Therapeutics Awarded CARB-X Grant to Support Development of ETX0282CPDP

Entasis Therapeutics Receives Second CARB-X Award, Providing up to $10.1 Million for Development of Non-Beta-lactam PBP Inhibitor Program

Entasis Therapeutics Performs Strongest Among 12 Biopharmaceutical Companies in the Access to Medicine Foundation’s Antimicrobial Resistance Benchmark 2018

Entasis Receives $10M Investment from the REPAIR Impact Fund to Support NBP Program